The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / The State of Clinical Science for Pediatric Rheumatology in 2021

The State of Clinical Science for Pediatric Rheumatology in 2021

December 2, 2021 • By Elizabeth Sloan, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

ACR Convergence 2021—The Pediatric Rheumatology Year in Review began with a fascinating talk by Mara Becker, MD, MSCE, a professor of Pediatrics and vice chair of faculty at Duke University School of Medicine, Durham, N.C.

You Might Also Like
  • Pediatric Rheumatology Year in Review, 2021: Basic Science
  • ACR Releases COVID-19 Clinical Guidance for Pediatric Patients
  • Achieving Excellence in Pediatric Rheumatology Clinical Care
Explore This Issue
January 2022

Dr. Becker began by describing her search strategy to select high-yield clinical science publications in pediatric rheumatology from the past year. She queried the Medline search database, gathered content from the Pediatric Rheumatology Symposium (PRSYM), held earlier this year, and added a few of her favorite articles to identify important themes and publications. Although COVID-19 continued to dominate much of her literature search, she identified several other relevant topics, and her selections fell into these distinct themes: COVID-19 and multi-system inflammatory syndrome in children (MIS-C), disparities in pediatric rheumatology, and therapeutic optimization and innovation.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

COVID-19 & MIS-C

Dr. Becker

To begin the discussion of COVID-19 and MIS-C, Dr. Becker highlighted the two clinical guidance documents developed by the ACR. These provide recommendations for recognizing and treating children with MIS-C and on managing primary COVID-19 infection in children with rheumatic disease.1,2 She applauded the efforts of the ACR, Henderson et al. and Wahezi et al. for developing these guidance documents and for continuing to update the recommendations as new data emerge.

Dr. Becker continued by highlighting a publication by Son et al. that looked at initial therapy and outcomes in children treated with immunomodulating therapy for MIS-C. This study analyzed data from more than 500 patients from 58 hospitals in the U.S. The investigators used propensity score matching to compare outcomes between patients treated with intravenous immunoglobulin (IVIG) alone vs. those treated with IVIG plus glucocorticoids.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The researchers found that treatment with IVIG plus glucocorticoids was associated with a lower risk of adverse cardiovascular outcomes, and overall, the patients who received this combination treatment required less subsequent adjunctive immunomodulatory therapy. These results were published in the New England Journal of Medicine.3

The next COVID-19 article Dr. Becker covered was a review by Wahezi et al. discussing how the pandemic has affected the field of pediatric rheumatology.4 In addition to reviewing the abridged ACR guidelines, this paper also discussed advances in telerheumatology, post-COVID-19 sequelae, the impact of psychologic distress related to the pandemic and inequities that have emerged since the onset of the pandemic.

Her final selection from the COVID-19 pediatric literature was a study from Children’s Mercy Hospital, Kansas City, Mo., investigating the use of saliva to test for SARS-CoV-2. Researchers used paired testing of nasopharyngeal swabs and saliva in a small cohort of children receiving standard-of-care testing for COVID-19. Saliva samples demonstrated a high sensitivity and specificity, as well as a significant amount of viral load, suggesting that saliva testing may be a reasonable alternative to nasopharyngeal swabs for pediatric COVID-19 testing.5

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 5 6 | Single Page

Filed Under: ACR Convergence, Meeting Reports Tagged With: ACR Convergence 2021, Clinical, COVID-19, JIA, Multisystem Inflammatory Syndrome in Children (MIS-C), Pediatric, Pediatric Rheumatology, polyarticular juvenile idiopathic arthritis (JIA)Issue: January 2022

You Might Also Like:
  • Pediatric Rheumatology Year in Review, 2021: Basic Science
  • ACR Releases COVID-19 Clinical Guidance for Pediatric Patients
  • Achieving Excellence in Pediatric Rheumatology Clinical Care
  • 10 Clinical Insights & Rheumatology Pearls Presented at ACR Convergence 2021

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)